Bio-Techne Corp (TECH) Stock Price, Quote & News

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth f...

Industry: Biotechnology

Sector: Healthcare

Phone: 612 379 8854

Fax: 612 656 4400

Website: www.bio-techne.com

Address:

614 McKinley Place N.E., Minneapolis, United States

SPYmyQQQ Oct. 24 at 3:54 PM

🏛️ 🚀 $TECH up ⬆️29.69% since our entry $51.63 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

SPYmyQQQ Oct. 23 at 2:31 PM

🏛️ 🚀 $TECH up ⬆️26.67% since our entry $51.63 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

ZacksResearch Oct. 23 at 11:05 AM

$TECH Q1 earnings on deck — but can Protein Sciences strength offset Spatial Biology weakness? Steady Protein Sciences growth may help, but funding uncertainty from NIH and biotech could pressure Spatial Biology results. Full preview and key watchpoints here 👉 https://www.zacks.com/stock/news/2774904/bio-techne-q1-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2774904-teaser-17212&ADID=SYND_STOCKTWITS_TWEET_2_2774904_TEASER_17212

0 · Reply

MoneyGroupLLC Oct. 17 at 5:51 PM

Enter: $TECH NOV 21 2025 $60 CALLS Buy in Price: $3.89 - $6.00 Take Profit: $6.11 Stop Bleeding: $3.42 ROI Potential: 57% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

SuperGreenToday Oct. 16 at 10:36 PM

$TECH Share Price: $61.61 Contract Selected: Apr 17, 2026 $60 Calls Buy Zone: $1.40 – $1.73 Target Zone: $2.40 – $2.93 Potential Upside: 62% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Estimize Oct. 16 at 11:00 AM

Wall St is expecting 0.42 EPS for $TECH Q1 [Reporting 11/05 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

JarvisFlow Oct. 14 at 12:58 PM

TD Cowen updates rating for Bio-Techne ( $TECH ) to Buy, target set at 65 → 70.

0 · Reply

ZacksResearch Oct. 8 at 1:07 PM

$TECH down 20.3% in a year compared to the industry’s 5.8% fall — is it time to reconsider? 📉 Despite strong international growth and strategic acquisitions like Lunaphore, macro pressures and competition are squeezing margins. The stock's been lagging, even as the S&P 500 rose 18.7% in the same period. Discover the full TECH story here 👉 https://www.zacks.com/stock/news/2764249/should-you-continue-to-hold-bio-techne-stock-in-your-portfolio?cid=sm-stocktwits-2-2764249-body-15064&ADID=SYND_STOCKTWITS_TWEET_2_2764249_BODY_15064

0 · Reply

ZacksResearch Oct. 8 at 12:07 PM

$TECH — Hold or fold? Here’s what investors need to know. Bio-Techne’s performance and outlook are under review as the latest analysis digs into whether the stock still deserves a spot in long-term portfolios. Full breakdown here 👉 https://www.zacks.com/stock/news/2764249/should-you-continue-to-hold-bio-techne-stock-in-your-portfolio?cid=sm-stocktwits-2-2764249-teaser-15049&ADID=SYND_STOCKTWITS_TWEET_2_2764249_TEASER_15049

0 · Reply

SuperGreenToday Oct. 3 at 7:48 PM

$TECH Share Price: $63.12 Contract Selected: Apr 17, 2026 $65 Calls Buy Zone: $6.54 – $8.09 Target Zone: $10.82 – $13.23 Potential Upside: 56% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital

Oct 15, 2025, 9:00 AM EDT - 9 days ago

Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents

Oct 15, 2025, 7:00 AM EDT - 9 days ago

Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results

Oct 9, 2025, 7:00 AM EDT - 15 days ago

Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032

Sep 26, 2025, 6:30 AM EDT - 4 weeks ago

Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications

Sep 24, 2025, 6:59 AM EDT - 4 weeks ago

Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report

Sep 10, 2025, 2:36 PM EDT - 6 weeks ago

Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:36 AM EDT - 6 weeks ago

Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 9, 2025, 7:00 AM EDT - 6 weeks ago

ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

Sep 3, 2025, 3:42 PM EDT - 7 weeks ago

Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne to Present at Upcoming Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 2 months ago

ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

Aug 6, 2025, 12:52 PM EDT - 2 months ago

Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript

Aug 6, 2025, 8:08 AM EDT - 2 months ago

Bio-Techne beats quarterly estimates on strength in protein sciences unit

Aug 6, 2025, 6:30 AM EDT - 2 months ago

BIO-TECHNE DECLARES DIVIDEND

Aug 6, 2025, 6:30 AM EDT - 2 months ago

Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

Aug 5, 2025, 4:30 PM EDT - 2 months ago

Bio-Techne Announces Exosome Diagnostics Divestiture

Aug 5, 2025, 7:00 AM EDT - 2 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine

Jul 31, 2025, 9:52 AM EDT - 3 months ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

Jul 31, 2025, 7:00 AM EDT - 3 months ago

ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering

Jul 28, 2025, 1:19 PM EDT - 3 months ago

Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell

Jul 17, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

Jul 15, 2025, 9:03 AM EDT - 3 months ago

Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology

Jul 15, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

Jul 14, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

ABEO

Jun 24, 2025, 7:00 AM EDT - 4 months ago

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Jun 10, 2025, 7:00 AM EDT - 4 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

May 29, 2025, 7:00 AM EDT - 5 months ago

Bio-Techne to Present at Investor Conferences

May 14, 2025, 7:00 AM EDT - 5 months ago

ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

May 12, 2025, 7:00 AM EDT - 5 months ago

Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

May 8, 2025, 9:30 AM EDT - 6 months ago

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

May 8, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

May 7, 2025, 10:38 AM EDT - 6 months ago

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

May 7, 2025, 8:18 AM EDT - 6 months ago

Bio-Techne exceeds profit expectations, announces new share buyback plan

May 7, 2025, 6:30 AM EDT - 6 months ago

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

May 7, 2025, 6:30 AM EDT - 6 months ago

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

May 6, 2025, 7:00 AM EDT - 6 months ago

ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.

Apr 29, 2025, 7:00 AM EDT - 6 months ago

ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy

Apr 24, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection

Apr 23, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 7 months ago

Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument

Mar 26, 2025, 7:00 AM EDT - 7 months ago

Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany

Mar 24, 2025, 7:00 AM EDT - 7 months ago

Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting

Mar 10, 2025, 7:00 AM EDT - 8 months ago

Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

Mar 3, 2025, 7:00 AM EST - 8 months ago

Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes

Feb 27, 2025, 9:00 AM EST - 8 months ago

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Feb 20, 2025, 7:00 AM EST - 8 months ago

Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology

Feb 18, 2025, 7:00 AM EST - 8 months ago

Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

Feb 5, 2025, 2:24 PM EST - 9 months ago

Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 6:30 AM EST - 9 months ago

Bio-Techne Declares Dividend

SPYmyQQQ Oct. 24 at 3:54 PM

🏛️ 🚀 $TECH up ⬆️29.69% since our entry $51.63 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

SPYmyQQQ Oct. 23 at 2:31 PM

🏛️ 🚀 $TECH up ⬆️26.67% since our entry $51.63 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

ZacksResearch Oct. 23 at 11:05 AM

0 · Reply

MoneyGroupLLC Oct. 17 at 5:51 PM

Enter: $TECH NOV 21 2025 $60 CALLS Buy in Price: $3.89 - $6.00 Take Profit: $6.11 Stop Bleeding: $3.42 ROI Potential: 57% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

SuperGreenToday Oct. 16 at 10:36 PM

0 · Reply

Estimize Oct. 16 at 11:00 AM

Wall St is expecting 0.42 EPS for $TECH Q1 [Reporting 11/05 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

JarvisFlow Oct. 14 at 12:58 PM

TD Cowen updates rating for Bio-Techne ( $TECH ) to Buy, target set at 65 → 70.

0 · Reply

ZacksResearch Oct. 8 at 1:07 PM

0 · Reply

ZacksResearch Oct. 8 at 12:07 PM

0 · Reply

SuperGreenToday Oct. 3 at 7:48 PM

0 · Reply

Fizz26 Oct. 3 at 4:07 PM

$DJIA $TECH keeps moving

0 · Reply

StockAutoPro Oct. 2 at 7:37 PM

$TECH: Buy target $58.75 Sell target $63.79 Strong earnings report suggests potential growth for this leading social media platform.

0 · Reply

SPYmyQQQ Oct. 2 at 7:23 PM

🏛️ 🚀 $TECH up ⬆️21.65% since our entry $51.63 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

Fizz26 Oct. 2 at 5:39 PM

$DJIA $TECH flying!!!

0 · Reply

Estimize Oct. 2 at 11:00 AM

Wall St is expecting 0.42 EPS for $TECH Q1 [Reporting 11/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

shitzushimazu Oct. 2 at 1:03 AM

$TECH holy shit techne about time

0 · Reply

SPYmyQQQ Oct. 1 at 5:01 PM

🏛️ 🚀 $TECH up ⬆️13.23% since our entry $51.63 on Sep 26, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!

0 · Reply

SPYmyQQQ Sep. 30 at 5:33 PM

🎯 Target Hit 🏁 📨 Signal From Sep 26, 2025 🏛️ $TECH 💵 Entry: $51.6300 ✅ Exit: $52.6678 💰 P/L: +2.01% 👉 Check bio for full access

0 · Reply

ZacksResearch Sep. 29 at 1:45 PM

$TECH unveils spatial biology advancements — will it spark a stock rally? 🌐 Bio-Techne's RNAscope & COMET innovations could boost clinical workflows, while its 3.9% earnings yield stands strong against an industry at -21.1%. However, $TECH holds a Zacks Rank #4 (Sell), so tread carefully. Discover the full story here 👉 https://www.zacks.com/stock/news/2758627/bio-techne-stock-climbs-on-advances-in-spatial-biology-solutions?cid=sm-stocktwits-2-2758627-body-14445&ADID=SYND_STOCKTWITS_TWEET_2_2758627_BODY_14445

0 · Reply

ZacksResearch Sep. 29 at 12:45 PM

$TECH on the move 🚀 — spatial biology gains are driving the stock higher. Advances in RNAscope and COMET are highlighting new roles in lymphoid malignancy diagnostics, giving fresh momentum to the story. Full breakdown here 👉 https://www.zacks.com/stock/news/2758627/bio-techne-stock-climbs-on-advances-in-spatial-biology-solutions?cid=sm-stocktwits-2-2758627-teaser-14444&ADID=SYND_STOCKTWITS_TWEET_2_2758627_TEASER_14444

0 · Reply

SPYmyQQQ Sep. 26 at 3:02 PM

🚀 New Signal ✅ 🏛️ $TECH 🗓️ Sep 26, 2025 💵 Entry: $51.63 🎯 Target (Opt.): $52.67 (+2.01%) 👉 Check bio for full access

0 · Reply

MoneyGroupLLC Sep. 26 at 6:57 AM

Enter: $TECH OCT 17 2025 $55 CALLS Buy in Price: $0.92 - $1.35 Take Profit: $1.22 Stop Bleeding: $0.81 ROI Potential: 33% Exit Within: 148 Minutes https://moneygroup.us/alerts

0 · Reply

Market Cap	10.29B
Revenue (ttm)	1.22B
Net Income (ttm)	73.40M
EPS (ttm)	N/A
PE Ratio	36.87
Forward PE	36.04
Profit Margin	6.02%
Debt to Equity Ratio	0.18

Volume	1,806,800
Avg Vol	2,312,982
Day's Range	N/A - N/A
Shares Out	155.69M
Stochastic %K	88%
Beta	1.48
Analysts	Strong Sell
Price Target	$67.15